Since the introduction of methicillin into clinical medicine in 1959 the prevalence of Staphylococcus aureus strains resistant to this antibiotic has reached epidemic proportions in certain geographic areas. The therapeutic options for treating such strains are largely limited to vancomycin. The ll-lactamase-resistant penicillins and cephalosporins have been controversial for the treatment of infections caused by these organisms [1] .
Beta-lactamase inhibitors (e.g., clavulanic acid and sulbactam) have a weak intrinsic antibacterial activity but act synergistically with ll-lactamase-labile antibiotics against most ll-lactamase-producingorganisms such as methicillinsensitive S. aureus (MSSA) . In the case of methicillinresistant S. aureus (MRSA), the resistance mechanisms are more complex and lesswellunderstood [1] . However,when the ll-lactamases of MRSA strains are inhibited by the addition of clavulanic acid, the minimal inhibitory concentrations (MICs) of amoxicillin and penicillin against these organisms are reduced by 2-4 dilutions to values of 4-16 ug/ml, for most of the strains tested [2] [3] [4] . While many authors consider this increase in in vitro activity to be of questionable significance, Washburn and Durack [5] showed with a rabbit model of S. aureus endocarditis that the combination of ampicillin and sulbactam was highly effective against endocarditis caused by two different nafcillin-resistant S. aureus strains and that the combination was superior to nafcillin alone. Because these in vitro and in vivo observations deserve further scrutiny, we designed this study: (1) to determine the MICs of amoxicillin and oxacillin, alone or in combination with clavulanic acid, for a large number of recent clinical isolates of MSSA and MRSA; and (2) to study the in vivo efficacy of the combination of amoxicillin with clavulanic acid against MSSA and MRSA strains in a rat model of S. aureus endocarditis and to compare it to that of cloxacillin and vancomycin.
Materials and Methods
In vitro study. (1) Microorganisms. A total of 167 strains of S. aureus originating in different locales (Eu-rope, the USA, Australia) were studied. All of the strains were ll-lactamase producers and thus wereresistant to penicillin. When tested by a disk diffusion method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) [6] , 71 strains were found to be methicillin-sensitive (Kirby Bauer inhibition diameter~13 mm using a l-ug oxacillin disk in Mueller Hinton agar [MH; Difco Laboratories, Detroit] without NaCl). Ninetysix strains were methicillin-resistant (Kirby Bauer inhibition diameter "10 mm under the same testing conditions).
(2) Antibiotics. Standard (3) Susceptibility testing. MICs weredetermined by the microbroth dilution method [7] with an automatic device (MIC 2000 Dynatech, FRO). MICs of oxacillin, amoxicillin, and oxacillin in combination with clavulanic acid (added at a fixed concentration of 4 ug/ml.), and amoxicillin-clavulanic acid (in a ratio of 2:1), were performed in cation-supplemented MHB (50 mg/L of Ca" and 25 mg/L of Mg") with 20/0 NaCl. For vancomycin MIC determinations, cation supplementation was not used. Final inocula of 5 x lOS to 5 X 10 6 cfu/mL were prepared from an overnight culture in MH. MICs were determined by visual inspection after 24 h of incubation at 35°C. For a selection of strains, MBC were determined by macro broth dilution method [8] and defined as the lowest concentration of antibiotic that killed 99.9% of the initial inoculum after 24 h of incubation.
In vivo study. (1) Microorganisms. Four different strains of S. aureus were studied in the rat model: two MSSA (MSSA-l, MSSA-2) and two MRSA (MRSA-l, MRSA-2).
(2) Production ofendocarditis. Sterilevegetationswere produced in female Wistar rats (180-200 g) by modification of a method already described [9] . Briefly, a polyethylene catheter (PP 10, Portex, Hythe, Kent, UK) was inserted across the aortic valve through the right carotid artery and secured with a silk ligature. Rats were injected in the tail vein with 0.5 mL of saline containing 10 5 cfu of S. aureus (MSSA-I, MSSA-2, MRSA-I, or MRSA-2) either 4 d (half of the experiments) or 12 h after catheterization. Both experimental designs produced bacterial counts of 10 6_107 cfu/g of vegetations 12 h after iv bacterial challenge. Since the effect of treatment was found to be similar after both experimental designs (bacterial challenge 4 d and 12 h after catheterization), the results were pooled.
(3) Evaluation ofinfection. To determine the incidence and the magnitude of valvular infection, control rats cho-sen at random were sacrificed 12 h after iv injection of bacteria (i.e., at the time treatment was started in the test rats). Treated rats were killed after 3 d of therapy, 12 h after the last antibiotic injection, when no antibiotic activity was detectable in blood. Aortic vegetations were excised, weighed, homogenized in 1 mL of saline, and serially diluted and plated. Colonies were counted after 24 h of incubation at 37°C, and the results expressed in 10g10 cfu/g of vegetation. This method permitted the detection of lQ2 cfu/g of organ. Bacteria recovered from the vegetations of treated rats were routinely stored at -20°C for subsequent MIC determinations. 
Results
In vitro study. (1) MSSA strains. Figure 1 (upper panels) illustrates results. Of the MSSA strains, 62 (87%) of71 wereresistant to amoxicillin according to the criteria of the NCCLS (MIC~0.5 ug/ml.) [7] : MIC so 8 ug/ml.; MIC go 128 ug/ml.; range~0.12-256 ug/ml., The addition of clavulanic acid reduced the MIC so for amoxicillin to 1 ug/rnl., the MICgo to 2 ug/ml., and the range tõ O.l2-4l1g/mL, making thestrains susceptibleto Augmentin (MIC~4/2 ug/ml.). All strains were susceptible to oxacillin (MIC so 0.25 I1g/mL, MIC go 0.5 I1g/mL, rangẽ O.l25-1.0 ug/ml.), and their MICs were only slightly influenced by the addition of clavulanic acid (MIC so~. 012 ug/ml.; MIC 90 0.25 ug/ml.; range~O.l2-o.5l1g/mL). All MSSA strains were also susceptible to vancomycin (MIC so 1 ug/ml.; MICgo 1 j.Lg/mL; range 1-2 ug/ml.).
(2) MRSA strains. The lower panels of figure 1 illus-
Concise Communications
trate the results. The addition of clavulanic acid reduced the amoxicillinMIC so from 32 to 8I1g/mL, the MIC 90 from 128to 16I1g/mL, and the range from 8-128to 2-32 ug/ml., but most of these organisms remained resistant to Augmentin according to the criteria of the NCCLS (MIC8 /4 ug/ml.). In contrast, the addition of clavulanic acid to oxacillin did not influence the MIC (oxacillin MIC so in the presence of clavulanic acid 32 ug/rnl., MIC go 128 I1g/mL,range 2-256I1g/mL); most strains remained highly resistant. All of the MRSA strains weresusceptible to vancomycin (MICso, l ug/ml.: MIC go 2 ug/rnl.; range 0.25-2 I1g/mL).
In vivostudy. (2) Antibioticserumlevels. After a dose of 150mg/kg of amoxicillin-clavulanatesc the peak serum levelof amoxicillin reached 93 ± 31I1g/mL, dropping to no detectable levels after 4 h. The peak serum level of clavulanic acid was 21 ± 7 I1g/mL and after 2 h no clavulanic acid was detectable. After one injection of cloxacillin 200 mg/kg sc, the peak serum level exceeded 200 ug/rnl., but no antibiotic was found in serum 4 h later. One injection of vancomycin 30 mg/kg sc resulted in a peak of 36 ug/ml., however, levelswereundetectable 6 h later. Thus, at the dosage used in rats, the antibiotics used in these experiments reached peak levels comparable to those in humans after conventional therapeutic doses.
Comparative efficacyoftreatment for 3 d. (1) MSSA strains. Cloxacillin given at 200 mg/kg every 5 h, and amoxicillin/clavulanate given at 150mg/kg every 5 h were both highly and equally effective (P < 10-10 compared to controls), sterilizing more than 90% of the infected vegetations ( figure 2, upper part) . The vancomycin 30 mg/kg regimen given twice a day (figure 2) was effective in reducing valvular infection (P < 10-2 compared to controls), but remained less active than cloxacillin and amoxicillinclavulanate. When the vancomycin dosage was increased to 30 mg/kg every 6 h ( figure 2, upper right) , the efficacy of the three different antibiotics became similar.
(2) MRSA strains. As expected, the cloxacillin regimen clearly failed to cure infection and all of the rats remained highly infected after 3 d of treatment (figure 2, lower panels). In contrast, amoxicillin-clavulanate showed a definite efficacy against both MRSA strains (P < lO-s with MRSA-l and P < 10- used against the MRSA-I strain failed to produce a significant effect on the valvular counts whencompared to controls (P = .6); increasing the doses to four times a day only marginally improved the outcome of infection (P = .1 when compared to controls). Against the MRSA-2 strain, vancomycin given four times a day improved outcome whencompared to controls(P = .01) and to cloxacillin (P = .01), but was clearly less effective than amoxicillin-clavulanate (P = .02)(figure 2, lower right). MICsof bacteriarecovered from rats that remained infected at the end of the various treatments were equal to those of the organisms used for the bacterial challenge.
Discussion
Thisstudyof the treatmentof methicillin-resistant S. aureus endocarditis in rats revealed three interesting observations. (1) Clavulanic acid markedly reduced the amoxicillin-resistance of the MRSA strains in vitro, but had littleeffecton the oxacillin-resistance of thoseorganisms. (2)Thecombination of amoxicillin-clavulanate (Augmentin) wasvery effective in vivo not onlyagainstMSSA but also, and moreimportantly, against MRSA strains that were marginally susceptible to this combinationin vitro according to current MIC interpretive standards [7] . (3) Yancomycin was less active in vivo than amoxicillinclavulanate against MRSA strains, whereas it was uniformly active against these organisms in vitro.
With regard to the in vitro results, most of the MRSA strains are also a-Iactamase producers so that penicillin derivatives otherthan penicillinase-resistant penicillins are rarely if ever tested against them. When clavulanic acid isassociated witha-Iactam antibiotics to neutralize theeffect of a-Iactamases, an enhanced in vitro effect of the penicillinase sensitive penicillins whencompared to that of the penicillinase resistant penicillins alone can be observed on MRSA strains. This phenomenon has already been observed both with amoxicillin-clavulanate combination [2] [3] [4] and withan ampicillin-sulbactam combination [10, 11] , and mightrelateto the observation that penicillin and amoxicillin display a greater in vitro activity on penicillin-sensitive S. aureus strains than do such penicillinase-resistant penicillins as oxacillin or methicillin. This difference in intrinsicactivity may be ascribed to differences in the targetmolecules to which the respectivea-Iactam antibiotics attach, e.g., differences in target penicillin binding proteins [4] . Such differences may explain why the addition of clavulanic acid to oxacillin had no beneficial effect on the MICs of MRSA strains while it improved the MIC of amoxicillin.
With regard to the marked in vivo efficacy of amoxicillin-clavulanate against MRSA strains, Washburn and Durack [5] obtained similar results with a combination of ampicillin and sulbactam in a rabbit model of endocarditis infected with a nafcillin-resistant S. aureus. As in our study, according to the MIC interpretive standards, the strains studied by Washburn and Durack were only marginally sensitive in vitro to the combination of ampicillinand p-lactamase inhibitor. The MIC for sulbaetamampicillin was 25 ug/ml, in the Washburn-Durack experiments, while the amoxicillin-clavulanate MIC was 16 ug/rnl, for both MRSA strains in-our experiments. Thus, both studies suggest that despite moderate in vitro sensitivities, the combination of ampicillin (respectiveof amoxicillin) with a p-lactamase inhibitor might exhibit excellent effectiveness in vivo. The doses used in both animal models of endocarditis (rabbit and rat) were chosen so as to give serum levels similar to those achieved in humans receiving full parenteral therapy.
With respect to the in vitro interpretive standard for sensitivity or resistance of staphylococci to amoxicillinclavulanate (resistant category, MIC~8 I1g/mL), most of the MRSA strains were resistant in our study, having an MIC of 8 or 16I1g/mL. If one considers, however, the similar break-point value proposed for organisms other than staphylococci, most of the strains would be considered to be susceptible (MIC~8 I1g/mL) or moderately susceptible (MIC = 16I1g/mL) to the combination. Likewise, the usual MIC values of the MSSA strains for amoxicillin-clavulanate are near the upper limit of susceptibility (~4I1g/mL), if one considers the category MIC break points for staphylococci only. Given the success of treatment with a combination of ampicillin (amoxicillin) plus clavulanic acid achieved in experimental endocarditis due to several MRSA strains, perhaps it would be worthwhile to reconsider the interpretive break points for MICs currently recommended for Augmentin against staphylococci [6] .
With regard to the efficacy of vancomycin against the MRSA strains, while it showed an excellent in vitro activity, its in vivo efficacy was inferior to that of amoxicillinclavulanate after 3 d of treatment. While unpublished experiments have shown that this difference disappeared after 6 d of treatment, amoxicillin-clavulanate sterilized the vegetations faster than did vancomycin.
Thus, the association of amoxicillin and clavulanic acid (Augmentin) was shown to be effective in the treatment of experimental endocarditis due to both MSSA and MRSA strains. 
